What is the appropriate diagnostic workup and management of vaginitis in an adult patient?

Management of Vaginitis in Adults

The diagnostic workup of vaginitis requires objective testing with wet mount microscopy, vaginal pH, and KOH preparation (or preferably molecular testing when available), followed by targeted antimicrobial therapy based on the specific etiology identified: metronidazole for trichomoniasis and bacterial vaginosis, or azole antifungals for vulvovaginal candidiasis.

Diagnostic Approach

Essential Clinical Assessment

The diagnosis cannot be made reliably on symptoms alone, as pruritus, discharge, odor, burning, and dyspareunia overlap significantly across all three major causes 1. Objective testing at the time of symptoms is critical to establishing the correct diagnosis 2, 3.

Diagnostic Testing

Point-of-care testing should include:

• Vaginal pH measurement: pH ≤4.5 suggests vulvovaginal candidiasis; pH >4.5 suggests bacterial vaginosis or trichomoniasis 1
• Wet mount microscopy: Look for yeast/pseudohyphae (candidiasis), clue cells (bacterial vaginosis), or motile trichomonads (trichomoniasis) 1
• 10% KOH preparation: Improves visualization of yeast by disrupting cellular material; positive "whiff test" suggests bacterial vaginosis 1

Molecular testing (NAAT/PCR) is superior to microscopy with sensitivity of 90.9% versus 57.5% for clinical diagnosis and should be used when available 1, 2. Culture remains the gold standard for candidiasis when microscopy is negative but symptoms persist, and for identifying non-albicans species 1. For trichomoniasis, microscopy has only 60-70% sensitivity, making culture or NAAT preferred 1.

Common pitfall: Approximately 50% of patients treated for vaginitis receive therapy without objective diagnosis, leading to treatment failures 1, 4. Additionally, 10-20% of asymptomatic women harbor Candida species; positive culture without symptoms should not prompt treatment 1.

Treatment by Etiology

Trichomoniasis

Recommended regimen: Metronidazole 2 g orally as a single dose 1

Alternative regimen: Metronidazole 500 mg orally twice daily for 7 days 1

Both regimens achieve 90-95% cure rates 1. Metronidazole gel is not recommended as it achieves <50% efficacy due to inability to reach therapeutic levels in the urethra and perivaginal glands 1.

Treatment failure management:

• First failure: Re-treat with metronidazole 500 mg twice daily for 7 days 1
• Second failure: Metronidazole 2 g once daily for 3-5 days 1
• Persistent failure: Consult specialist for susceptibility testing 1

Critical management points:

• Treat all sex partners to prevent reinfection 1
• Instruct patients to abstain from sex until both partners complete therapy and are asymptomatic 1
• Test for other STIs (chlamydia, gonorrhea, HIV) as trichomoniasis is sexually transmitted 1, 4
• Pregnancy: Safe to use metronidazole 2 g single dose in any trimester 1
• HIV-positive patients: Same treatment regimen 1

Vulvovaginal Candidiasis (VVC)

For uncomplicated VVC (mild-to-moderate, sporadic, C. albicans in immunocompetent host):

Over-the-counter intravaginal options 1:

• Clotrimazole 1% cream 5 g daily for 7-14 days
• Miconazole 2% cream 5 g daily for 7 days
• Miconazole 200 mg suppository daily for 3 days
• Tioconazole 6.5% ointment 5 g single application

Prescription options 1:

• Fluconazole 150 mg oral single dose (most convenient)
• Terconazole 0.4% cream 5 g daily for 7 days
• Terconazole 80 mg suppository daily for 3 days

All azole regimens achieve 80-90% cure rates 1. Topical azoles are more effective than nystatin 1.

For complicated VVC (severe symptoms, recurrent episodes, non-albicans species, immunocompromised, uncontrolled diabetes, pregnancy):

• Requires longer treatment duration (7-14 days of topical azole therapy) 1
• Culture recommended to identify non-albicans species 1
• Recurrent VVC (≥4 episodes/year): Consider extended suppressive therapy after initial treatment 1, 2

Special considerations:

• Pregnancy: Use only topical azole therapy; oral fluconazole is not recommended 1
• HIV-positive patients: Same treatment regimen 1
• Partner treatment is not necessary as VVC is not sexually transmitted 1

Bacterial Vaginosis

While the provided evidence focuses primarily on trichomoniasis and candidiasis, bacterial vaginosis treatment includes metronidazole 500 mg orally twice daily for 7 days or intravaginal metronidazole/clindamycin preparations 1.

Key Clinical Pitfalls

Avoid empiric treatment without diagnosis: Studies show 55.2% of empiric prescriptions are ineffective or unnecessary 5. Only 17% of patients evaluated for trichomoniasis and 45% for bacterial vaginosis receive optimal diagnostic workup 4.

Recognize diagnostic limitations: Limited access to all three point-of-care tools (microscope, pH strips, KOH) occurs in 68% of primary care practices 4. Consider molecular testing when available 1, 2.

Consider non-infectious causes: If symptoms persist despite appropriate therapy with negative testing, evaluate for desquamative inflammatory vaginitis, genitourinary syndrome of menopause, or vulvodynia 2, 3.

Recurrent cases require specialist referral: Complex cases with atypical symptoms, negative testing, or refractory symptoms despite appropriate therapy warrant specialist evaluation 3.